Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis

Figure 1 Cumulative probability of colorectal cancer or dysplasia (A), cumulative incidence of immunosuppressors use (B), cumulative incidence of colonic or ileal surgical resection (C), from the IBD diagnosis date in cases (those with inflammatory bowel disease -associated with primary sclerosing cholangitis) vs controls (those with IBD without PSC).

Figure 2 Overall survival from IBD diagnosis date in cases (those with inflammatory bowel disease associated with primary sclerosing cholangitis) vs controls (those with chronic ulcerative colitis). Follow up was censored for those who underwent orthotopic liver transplantation.